NHS National Generic Pharmaceuticals Wave 13
Estimated value
—
Awarded value
—
Suppliers
192
Lots
3
Published
14 Jan 2022
Description
Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months)
Scope
- Reference
- CM/PHG/17/5532
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 192 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 3 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus) | — | cancelled |
| 2 | Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals | — | cancelled |
| 3 | Lot 3 - CM/PHG/17/5532/02 Hospital Only Products | — | cancelled |